
Hartej Gill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4104439/publications.pdf Version: 2024-02-01



HADTEL CILL

#	Article	IF	CITATIONS
1	Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs, 2022, 36, 17-30.	2.7	45
2	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2022, 101, 93-135.	2.0	670
3	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 300, 449-461.	2.0	34
4	The effects of antidepressant medications on antiretroviral treatment adherence in HIV-positive individuals with depression. Journal of Affective Disorders, 2022, 300, 219-225.	2.0	3
5	Immune response to vaccination in adults with mental disorders: A systematic review. Journal of Affective Disorders, 2022, 304, 66-77.	2.0	14
6	Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infectious Diseases, 2022, 54, 467-477.	1.4	42
7	The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. Psychiatry Research, 2022, 313, 114577.	1.7	2
8	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110032.	2.5	6
9	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Psychopharmacology, 2021, 35, 128-136.	2.0	11
10	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Journal of Psychiatric Research, 2021, 134, 57-68.	1.5	58
11	The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. Neuroscience and Biobehavioral Reviews, 2021, 120, 78-85.	2.9	48
12	The Prevalence of Suicidal Behaviour in Fibromyalgia Patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110078.	2.5	7
13	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. Journal of Affective Disorders, 2021, 282, 160-164.	2.0	24
14	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). Journal of Psychiatric Research, 2021, 135, 311-317.	1.5	15
15	Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. Journal of Affective Disorders, 2021, 282, 448-453.	2.0	9
16	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. Psychiatry Research, 2021, 298, 113800.	1.7	7
17	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. Advances in Therapy, 2021, 38, 2795-2820.	1.3	19
18	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. Journal of Psychiatric Research, 2021, 137, 426-436.	1.5	27

Hartej Gill

#	Article	IF	CITATIONS
19	The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. Journal of Psychiatric Research, 2021, 137, 232-241.	1.5	25
20	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. Journal of Affective Disorders, 2021, 286, 360-369.	2.0	36
21	The impact of overweight/obesity on monetary reward processing: A systematic review. Journal of Psychiatric Research, 2021, 137, 456-464.	1.5	9
22	Inflammation and disease modification in bipolar disorders: Priority avenues for future research. Bipolar Disorders, 2021, 23, 442-444.	1.1	2
23	Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Journal of Psychiatric Research, 2021, 139, 71-81.	1.5	47
24	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. Journal of Affective Disorders, 2021, 290, 364-377.	2.0	159
25	Prevention and Management of Common Adverse Effects of Ketamine and EsketamineÂin Patients with Mood Disorders. CNS Drugs, 2021, 35, 925-934.	2.7	35
26	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). Psychiatry Research, 2021, 302, 113993.	1.7	16
27	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. Journal of Affective Disorders, 2021, 292, 714-719.	2.0	5
28	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. Journal of Affective Disorders, 2021, 293, 285-294.	2.0	28
29	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. Journal of Affective Disorders, 2021, 294, 592-596.	2.0	10
30	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. Journal of Psychiatric Research, 2021, 143, 209-214.	1.5	3
31	Frequency Analysis of Symptomatic Worsening Following Ketamine Infusions For Treatment Resistant Depression in a Real-World Sample: Results From the Canadian Rapid Treatment Centre of Excellence. Psychiatry Research, 2021, 307, 114321.	1.7	5
32	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. Psychiatry Research, 2020, 294, 113514.	1.7	156
33	Antidepressant Medications and Weight Change: A Narrative Review. Obesity, 2020, 28, 2064-2072.	1.5	62
34	Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Affective Disorders, 2020, 276, 570-575.	2.0	30
35	Impact of COVID-19 pandemic on mental health in the general population: A systematic review. Journal of Affective Disorders, 2020, 277, 55-64.	2.0	3,399
36	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. Journal of Affective Disorders, 2020, 276, 576-584.	2.0	118

Hartej Gill

#	Article	IF	CITATIONS
37	The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Review of Neurotherapeutics, 2020, 20, 1263-1273.	1.4	29
38	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disorders, 2020, 22, 831-840.	1.1	40
39	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Affective Disorders, 2020, 274, 903-910.	2.0	70
40	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. Journal of Affective Disorders, 2020, 272, 1-7.	2.0	28
41	Registered clinical trials investigating ketamine for psychiatric disorders. Journal of Psychiatric Research, 2020, 127, 1-12.	1.5	22
42	Mental, emotional, and behavioral effects of ketogenic diet for non-epileptic neuropsychiatric conditions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109947.	2.5	14
43	Development and implementation of guidelines for the management of depression: a systematic review. Bulletin of the World Health Organization, 2020, 98, 683-697H.	1.5	25
44	The long-term effect of bariatric surgery on depression and anxiety. Journal of Affective Disorders, 2019, 246, 886-894.	2.0	117